Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
International Centre for Diarrhoeal Disease Research, Bangladesh.
Am J Trop Med Hyg. 2022 Jan 10;106(3):979-984. doi: 10.4269/ajtmh.21-0679.
Acute respiratory infections are a leading cause of morbidity and mortality among young children globally. The objective of this study was to evaluate the impact of the Cholera-Hospital-Based-Intervention-for-7-days (CHoBI7) handwashing with soap and water treatment mobile health (mHealth) program on respiratory illness among diarrhea patients and their household members in urban Dhaka, Bangladesh. A cluster-randomized controlled trial of the CHoBI7 mHealth program was conducted among diarrhea patient households in Dhaka, Bangladesh. Patients were randomized to three arms: standard recommendation on oral rehydration solution use, health facility delivery of CHoBI7 plus mHealth (weekly voice and text messages for 12 months) (no home visits), and health facility delivery of CHoBI7 plus two home visits and mHealth. Respiratory symptoms were assessed during monthly clinical surveillance over the 12-month surveillance period. Respiratory illness was defined as rapid breathing, difficulty breathing, wheezing, or coughing. Two thousand six hundred twenty-six participants in 769 households were randomly allocated to three arms: 849 participants to the standard message arm, 886 to the mHealth with no home visits arm, and 891 to the mHealth with two home visits arm. Compared with the standard message arm, participants in the mHealth with no home visits arm (Prevalence Ratio [PR]: 0.89 [95% CI: 0.80, 0.98]), and the mHealth with two home visits arm (PR: 0.89 [95% CI: 0.81, 0.99]) had significantly lower respiratory illness prevalence over the 12-month program period. Our findings demonstrate that the CHoBI7 mHealth program is effective in reducing respiratory illness among diarrhea patient households.
急性呼吸道感染是全球导致婴幼儿发病和死亡的主要原因。本研究旨在评估霍乱-基于医院-持续 7 天的干预措施(CHoBI7)肥皂洗手和水治疗移动医疗(mHealth)方案对孟加拉国达卡市腹泻患者及其家庭成员呼吸道疾病的影响。在孟加拉国达卡市对腹泻患者家庭进行了 CHoBI7 mHealth 方案的集群随机对照试验。患者被随机分为三组:口服补液盐使用的标准建议、CHoBI7 和 mHealth 的卫生机构提供(12 个月的每周语音和短信)(无家访)以及 CHoBI7 和两次家访和 mHealth 的卫生机构提供。在 12 个月的监测期间,通过每月临床监测评估呼吸道症状。呼吸道疾病定义为呼吸急促、呼吸困难、喘息或咳嗽。2626 名参与者被随机分配到 769 个家庭的三个组中:849 名参与者分到标准信息组,886 名分到无家访 mHealth 组,891 名分到两次家访 mHealth 组。与标准信息组相比,无家访 mHealth 组(患病率比 [PR]:0.89 [95% CI:0.80,0.98])和两次家访 mHealth 组(PR:0.89 [95% CI:0.81,0.99])在 12 个月的项目期间呼吸道疾病的患病率显著降低。我们的研究结果表明,CHoBI7 mHealth 方案可有效降低腹泻患者家庭的呼吸道疾病发病率。
Int J Environ Res Public Health. 2022-10-8
Int J Environ Res Public Health. 2022-10-16
Cochrane Database Syst Rev. 2021-1-6